Improving survival of stage II‐III primary gastric signet ring cell carcinoma by adjuvant chemoradiotherapy

Li, Yang; Zhu, Zhikai; Ma, Fuhai; Xue, Liyan; Tian, Yantao

doi:10.1002/cam4.3342

Cited by 9 publications

(15 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our previous study found that not all signet ring cell gastric cancers were insensitive to chemotherapy, and its chemosensitivity was related to the CLDN18-ARHGAP26/6 fusion gene (54). Li explored the survival of stage II-III primary signet ring cell gastric carcinoma by adjuvant chemoradiotherapy (55). In this study, SRCC patients with stage II-III experienced improved overall survival after receiving adjuvant chemoradiotherapy, which provides several treatment implications.…”

Section: Discussionmentioning

confidence: 92%

Difference Between Signet Ring Cell Gastric Cancers and Non-Signet Ring Cell Gastric Cancers: A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

Background: There is controversy about the characteristics and prognostic implications of signet ring cell gastric cancers and non-signet ring cell gastric cancers.Objective: This study aims to evaluate clinicopathological characteristics and prognoses of signet ring cell carcinoma (SRCC) and non-signet ring cell carcinoma (NSRCC) of stomach.Methods: Studies compared between SRCC and NSRCC of the stomach after gastrectomy and published before September 1st, 2020, in the PubMed, Cochrane, and Embase databases, were identified systematically.Results: A total of 2,865 studies were screened, and 36 studies were included, with 19,174 patients in the SRCC group and 55,942 patients in the NSRCC group. SRCC patients were younger in age (P < 0.001), less likely to be male patients (P < 0.001), more afflicted with upper third lesions (P < 0.001), and presenting with more Borrmann type IV tumors (P = 0.005) than NSRCC patients. Lymph nodes metastasis was similar between SRCC and NSRCC patients with advanced tumor stage (OR: 0.86, 95% CI: 0.67–1.10, P = 0.23), but lower in the SRCC than NSRCC patients with early tumor stage (OR: 0.73; 95% CI: 0.56–0.98, P = 0.02). SRCC patients had comparable survival outcomes with NSRCC patients for early gastric cancers (HR: 1.05, 95% CI: 0.65–1.68, P < 0.001) but had significantly poor prognosis for patients with advanced tumor stage (HR: 1.50, 95% CI: 1.28–1.76, P < 0.001).Conclusions: Signet ring cell carcinomas of the stomach are an increasingly common histopathological subtype of gastric cancers. These kinds of patients tend to be younger in age and more often female. Although, signet ring cell gastric cancer is a negative prognostic factor for patients with advanced stage. The difference is that for early stage of signet ring cell gastric cancers, it has low lymph nodes metastasis rate and comparable prognosis with non-signet ring cell cancers.

show abstract

Section: Discussionmentioning

confidence: 92%

Difference Between Signet Ring Cell Gastric Cancers and Non-Signet Ring Cell Gastric Cancers: A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Patients with advanced gastric cancer are considered ineligible for surgery and therefore require radio-chemotherapy [ 16 , 17 ]. However, radio-chemotherapy is frequently associated with acute toxicity [ 11 , 18 ]. In TCM, the development of gastric cancer is attributed to the deficiency of positive Qi and the invasion of evil Qi, and the treatment of gastric cancer is guided by a comprehensive theory including disease precaution, disease control, and recurrence prevention.…”

Section: Discussionmentioning

confidence: 99%

“…Thus, clinical treatment for advanced gastric cancer usually requires radio-chemotherapy [ 8 ]. Radio-chemotherapy is currently one of the most effective means of cancer treatment [ 9 , 10 ]; however, it is associated with acute toxicity [ 11 ]. The treatment of gastric cancer in traditional Chinese medicine (TCM) features well-established theoretical guidance, including disease precautions, disease control, and recurrence prevention.…”

Section: Introductionmentioning

confidence: 99%

Clinical Efficacy of Acupuncture on Neoadjuvant Chemotherapy with Capecitabine plus Paclitaxel and Radiotherapy in Progressive Gastric Cancer

Miao

Liu

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Objective. To assess the clinical efficacy of acupuncture on neoadjuvant chemotherapy with capecitabine plus paclitaxel and radiotherapy in progressive gastric cancer. Methods. In this randomized, double-blind, controlled clinical trial, 70 patients with advanced gastric cancer receiving radio-chemotherapy between May 2018 and June 2020 were assessed for eligibility in our institution and recruited. They were assigned via the random number table method at a ratio of 1 : 1 to receive either neoadjuvant chemotherapy with capecitabine plus paclitaxel and radiotherapy (control group) or acupuncture on neoadjuvant chemotherapy with capecitabine plus paclitaxel and radiotherapy (intervention group). The outcome measures included symptom mitigation, quality of life, and traditional Chinese medicine (TCM) symptom scores. Results. The two groups showed similar results in abdominal circumference, intraabdominal pressure, and bowel sounds before treatment ( P > 0.05 ). Acupuncture plus conventional treatment was associated with better mitigation on intraabdominal pressure (11.08 ± 1.37 vs. 12.17 ± 2.68) and bowel sounds (4 [3, 4] vs. 3 [3, 4]) versus conventional treatment alone ( P < 0.05 ). No statistically significant difference in TCM symptom scores was observed between the two groups before treatment ( P > 0.05 ). Acupuncture plus conventional treatment resulted in a lower TCM symptom score (24.63 ± 4.56 points) versus conventional treatment (31.17 ± 4.91 points) ( P < 0.05 ). The eligible patients given acupuncture showed significantly higher scores of physical function, role function, emotional function, cognitive function, and social function (81.52 ± 5.37, 88.17 ± 5.17, 85.15 ± 6.71, 78.45 ± 5.85, and 80.98 ± 7.14) versus those without acupuncture (52.98 ± 8.23, 69.87 ± 5.54, 68.24 ± 9.22, 61.34 ± 6.27, and 64.79 ± 6.89) ( P < 0.05 ). Conclusion. Acupuncture is effective in the recovery of acute toxicity after radio-chemotherapy for patients with advanced gastric cancer, which provides a certain reference for clinical treatment and is worthy of application and promotion.

show abstract

“…The current gastric cancer therapy guiding principle has proven that combined modality therapy (CMT), for example, laparoscopic gastrectomy, should drastically amplify survival in gastric cancer patients, and postoperative chemoradiotherapy (CRT) or perioperative chemotherapy (CT) are the desired procedures for the therapy of localized gastric cancer(4) , (5). The percentage of T1 cancers has constantly expanded from 30.4% in 1995 to 61% in 2014, according to a nationwide survey in South Korea (6).…”

Section: Introductionmentioning

confidence: 99%

Analyzing Risk Factors for Second Malignancies in Early Gastric Carcinoma from the SEER Database

Song

Jin

Zhang

et al. 2023

Preprint

View full text Add to dashboard Cite

A retrospective study was conducted based on a large population analyzing GC patients treated between 2010 and 2015 to elucidate the clinical features and predictive risk factors for developing secondary primary malignancies (SPMs). The cumulative incidence of SPM in patients was determined using Kaplan‒Meier analysis. Competing risk analyses adjusted for mortality were used after stratified Cox proportional hazard regression models and multivariate analyses to identify independent SPM predictors. A total of 3,289 of 167,747 GC sufferers were included in our analytic cohort. Of these, 155 patients were diagnosed with SPM. Histologic types other than adenocarcinoma (AC) and signet ring cell carcinoma (SRCC) were independent risk factors for developing SPM (hazard ratio [HR] of 2.262, 95% confidence interval [CI] of 1.146–4.465, P = 0.019) in multivariate Cox regression analysis. The surgical method, including both biopsy/local excision (HR of 2.3, CI of 1.291–4.095, P = 0.005) and subtotal/total resection (HR of 1.947, CI of 1.028–3.687, P = 0.041), chemotherapy (HR of 1.527, CI of 1.006–2.316, P = 0.047 and histologic type (HR of 2.318, CI of 1.193–4.504, P = 0.013)), were independent risk factors in the competitive risk model. Meanwhile, in subgroup analyses stratified by chemotherapy, an increased risk of developing SPM was associated with older age. Furthermore, we developed and internally validated a nomogram for predicting the cumulative incidence of SPM in GC patients (C-index = 0.73 for 72 months). These findings suggested that in specific histologic types of GC, the lymph node infiltration region missed after local surgical resection and concomitant chemotherapy would have an increased risk of SPM.

show abstract

Improving survival of stage II‐III primary gastric signet ring cell carcinoma by adjuvant chemoradiotherapy

Cited by 9 publications

References 28 publications

Difference Between Signet Ring Cell Gastric Cancers and Non-Signet Ring Cell Gastric Cancers: A Systematic Review and Meta-Analysis

Difference Between Signet Ring Cell Gastric Cancers and Non-Signet Ring Cell Gastric Cancers: A Systematic Review and Meta-Analysis

Clinical Efficacy of Acupuncture on Neoadjuvant Chemotherapy with Capecitabine plus Paclitaxel and Radiotherapy in Progressive Gastric Cancer

Analyzing Risk Factors for Second Malignancies in Early Gastric Carcinoma from the SEER Database

Contact Info

Product

Resources

About